Blood protein in lung cancer could improve diagnosis and treatment

March 2, 2011

Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease — difficult to diagnose in its earliest and most treatable stages — and to develop drugs that stop lung cancer from spreading. Their study appears in ACS's Journal of Proteome Research.

In the report, Je-Yoel Cho and colleagues note that is the leading cause of cancer deaths worldwide. Lung cancer is so deadly because of its tendency to spread — or metastasize — to distant sites in the body, such as the liver or the brain. Early detection could improve survival rates, but it is very difficult to detect lung cancer at early stages with today's technology. To find a better diagnostic tool, the researchers studied the proteins in the blood of lung cancer patients in search of red flags that could signal the disease's presence. They focused on adenocarcinoma, which accounts for 1 in 3 cases and is the most rapidly increasing form of lung cancer in women.

Cho and colleagues found elevated levels of a called serum amyloid A (SAA) in the blood and lung tissue of lung adenocarcinoma patients, compared to healthy people. Their work showed that high amounts of SAA were unique to lung cancers (compared with other lung diseases or other cancers) and that the protein was involved in metastasis of cancer cells from the original tumor site. The researchers say that the protein could be used as a diagnostic marker for lung cancer and as a target for developing drugs that stop metastasis.

Explore further: Researchers develop blood test to detect lung cancer

More information: "Identification and Validation of SAA as a Potential Lung Cancer Biomarker and its Involvement in Metastatic Pathogenesis of Lung Cancer" Journal of Proteome Research.

Related Stories

Researchers develop blood test to detect lung cancer

July 31, 2006

Lung cancer is the leading cause of cancer death for both men and women in the United States and around the world, mainly because lung cancers are found in late stages and the best treatment opportunities already have been ...

CXCR4: A new drug target in lung cancer

April 29, 2010

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference ...

Biomarker shows potential for early diagnosis of lung cancer

October 14, 2010

A collaboration between physicians and scientists at UNC Lineberger Comprehensive Cancer Center and the University of Texas M.D. Anderson Cancer Center has demonstrated that a biomarker called TCF21 may be used to develop ...

Recommended for you

Making polymers from a greenhouse gas

July 28, 2015

A future where power plants feed their carbon dioxide directly into an adjacent production facility instead of spewing it up a chimney and into the atmosphere is definitely possible, because CO2 isn't just an undesirable ...

New material opens possibilities for super-long-acting pills

July 28, 2015

Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.